Publication Authors:
Choi, I; Moon, M; Trautmann, M, Hompesch; Sorli, C
Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany, October, 2018.
About this Poster:
Efpeglenatide is a long-acting GLP-1 R agonist in development for the treatment of type 2 diabetes. Efpeglenatide’s effects on the GLP-1 R suggest that it is a superagonist: a ligand that leads to greater maximal signalling and stimulation compared with the endogenous ligand.
